- Home
- BNBX vs XRTX Comparison
BNBX vs XRTX Comparison
Compare BNBX & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BNBX | XRTX |
|---|---|---|
| Founded | 1983 | 2011 |
| Country | United States | Canada |
| Employees | 26 | N/A |
| Industry | Other Consumer Services | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7M | 4.3M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | BNBX | XRTX |
|---|---|---|
| Price | $0.53 | $2.15 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 190.6K | 34.5K |
| Earning Date | 05-14-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $253.12 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.35 | $0.35 |
| 52 Week High | $6.17 | $3.60 |
Technical Indicators
Market Signals| Indicator | BNBX | XRTX |
|---|---|---|
| Relative Strength Index (RSI) | 55.74 | 44.90 |
| Support Level | $0.45 | $2.01 |
| Resistance Level | $0.61 | $3.03 |
| Average True Range (ATR) | 0.06 | 0.22 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 67.41 | 12.31 |
Price Performance
Historical ComparisonAbout BNBX Applied DNA Sciences Inc.
BNB Plus Corp focuses on digital asset treasury management of BNB. The group is unlocking institutional-grade access to the Binance ecosystem, delivering non-directional yield strategies and long BNB exposure, powering the future of blockchain through a transparent, actively managed BNB treasury. The Company's differentiated blends sophisticated DeFi yield generation with Binance-native opportunities, unlocking access to high-performance digital assets for investors traditionally excluded from the space.
About XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.